AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24571752 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA testing
Number of subjects: 1914
Study 24571752 — intervention group
Group type: COMPARATOR
Intervention: Standard screening
Number of subjects: 1914
Study 24571916 — intervention group
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine 50 mg/d
Number of subjects: 2156
Study 24571916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2156
Study 24571940 — intervention group
Group type: EXPERIMENTAL
Intervention: NLR ≥5
Number of subjects: 432
Study 24571940 — intervention group
Group type: COMPARATOR
Intervention: NLR <5
Number of subjects: 432
Study 24571940 — intervention group
Group type: COMPARATOR
Intervention: Low tertile NLR
Number of subjects: 432
Study 24571940 — intervention group
Group type: EXPERIMENTAL
Intervention: High tertile NLR
Number of subjects: 432
Study 24571940 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle tertile NLR
Number of subjects: 432
Study 24571940 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes mellitus
Number of subjects: 432
Study 24571940 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 432
Study 24572562 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfed infants
Number of subjects: 70
Study 24572562 — intervention group
Group type: COMPARATOR
Intervention: Formula-fed infants
Number of subjects: 70
Study 24572562 — intervention group
Group type: EXPERIMENTAL
Intervention: All feeding groups (pooled analysis)
Number of subjects: 70
Study 24573552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra low-dose IL-2 (100,000-200,000 IU/m(2) ×3 per week for 6 to 12 weeks)
Number of subjects: 16
Study 24573552 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra low-dose IL-2
Number of subjects: 16
Study 24574239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab, an antagonist of CTLA-4
Number of subjects: 2
Study 24574344 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro migration of CD45(dim)CD34(pos)CXCR4(pos)KDR(pos) cells
Number of subjects: 119
Study 24574344 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling of migrated cell counts
Number of subjects: 119
Study 24574344 — intervention group
Group type: EXPERIMENTAL
Intervention: Basal cell counts and migratory activity
Number of subjects: 119
Study 24574776 — intervention group
Group type: EXPERIMENTAL
Intervention: FIT1
Number of subjects: 779
Study 24574776 — intervention group
Group type: EXPERIMENTAL
Intervention: FITmax
Number of subjects: 779
Study 24576165 — intervention group
Group type: EXPERIMENTAL
Intervention: T-BiRD regimen (thalidomide 100 mg/day, lenalidomide 25 mg/day, dexamethasone 40 mg/day, clarithromycin 500 mg twice daily)
Number of subjects: 26
Study 24576165 — intervention group
Group type: EXPERIMENTAL
Intervention: T-BiRD regimen
Number of subjects: 26
Study 24576311 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off treatment in repeated 6-week cycles)
Number of subjects: 4471
Study 24576516 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran
Number of subjects: 56000
Study 24576516 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 56000
Study 24576792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sayana® Press (SP)
Number of subjects: 86
Study 24576792 — intervention group
Group type: COMPARATOR
Intervention: DMPA IM
Number of subjects: 86
Study 24576794 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (LNG) 150 mcg/ethinyl estradiol (EE) 20 mcg for 42 days, LNG 150 mcg/EE 25 mcg for 21 days, LNG 150 mcg/EE 30 mcg for 21 days and EE 10 mcg for 7 days
Number of subjects: 3701
Study 24576794 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel/ethinyl estradiol combined oral contraceptive
Number of subjects: 3701
Study 24576876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test (CPT)
Number of subjects: 63
Study 24576889 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24577061 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy young men
Number of subjects: 45
Study 24577061 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy older men
Number of subjects: 45
Study 24577061 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients
Number of subjects: 45
Study 24577164 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to chemotherapy
Number of subjects: 39
Study 24577564 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic PCD with situs ambiguus (SA)
Number of subjects: 767
Study 24577564 — intervention group
Group type: COMPARATOR
Intervention: Control participants with situs ambiguus (SA)
Number of subjects: 767
Study 24577748 — intervention group
Group type: EXPERIMENTAL
Intervention: BRAFi after IT (N = 32)
Number of subjects: 274
Study 24577748 — intervention group
Group type: COMPARATOR
Intervention: BRAFi initially (N = 242)
Number of subjects: 274
Study 24577748 — intervention group
Group type: COMPARATOR
Intervention: BRAFi discontinuation (N = 193)
Number of subjects: 274
Study 24577748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab after BRAFi discontinuation (N = 40)
Number of subjects: 274
Study 24579662 — intervention group
Group type: EXPERIMENTAL
Intervention: CNS hemangioblastomas in VHL patients
Number of subjects: 225
Study 24579886 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan-naproxen
Number of subjects: 621
Study 24579886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 24579926 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10 mg/d
Number of subjects: 58
Study 24579987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nobori biolimus-eluting stent (BES)
Number of subjects: 0
Study 24579987 — intervention group
Group type: COMPARATOR
Intervention: First-generation drug-eluting stents (DES)
Number of subjects: 0
Study 24581147 — intervention group
Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (specifically E/I MLD ratio)
Number of subjects: 89
Study 24581147 — intervention group
Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (LAA for the range -850 -1024 HU)
Number of subjects: 89
Study 24581147 — intervention group
Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (LAA for the range -850 -910 HU)
Number of subjects: 89
Study 24581147 — intervention group
Group type: EXPERIMENTAL
Intervention: CT air trapping criteria (Expiratory to inspiratory MLD ratio)
Number of subjects: 89
Study 24581147 — intervention group
Group type: EXPERIMENTAL
Intervention: CT air trapping criteria
Number of subjects: 89
Study 24581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal threats
Number of subjects: 1460
Study 24581550 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicidal attempts
Number of subjects: 1460
Study 24581956 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible insulin therapy (FIT) educational programme
Number of subjects: 30
Study 24582005 — intervention group
Group type: EXPERIMENTAL
Intervention: ADOS (Autism Diagnostic Observation Schedule) module 1
Number of subjects: 21
Study 24582005 — intervention group
Group type: EXPERIMENTAL
Intervention: ADOS score
Number of subjects: 21
Study 24582005 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant Development-Third Edition
Number of subjects: 21
Study 24582005 — intervention group
Group type: EXPERIMENTAL
Intervention: ASD-like social behaviors
Number of subjects: 21
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Service satisfaction
Number of subjects: 139
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 139
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline QOL scores
Number of subjects: 139
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms' severity
Number of subjects: 139
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual well-being
Number of subjects: 139
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Level of activity
Number of subjects: 139
Study 24582503 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 139
Study 24582505 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib 960 mg orally twice a day
Number of subjects: 3226
Study 24582522 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-donor uterus transplantation (UTx) with low-dose induction immunosuppression
Number of subjects: 9
Study 24582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nutrient drink (first part)
Number of subjects: 20
Study 24582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying of solids (second part)
Number of subjects: 20
Study 24582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying of liquids (second part)
Number of subjects: 20
Study 24582673 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized nutrient drink (third part)
Number of subjects: 20
Study 24583293 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (cTnT) assay
Number of subjects: 23
Study 24583293 — intervention group
Group type: EXPERIMENTAL
Intervention: Hourly sampling of cTnT
Number of subjects: 23
Study 24583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with normal AT results
Number of subjects: 203
Study 24583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with intermediate AT results
Number of subjects: 203
Study 24583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) with abnormal AT results
Number of subjects: 203
Study 24583305 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access (TRA) across all AT results
Number of subjects: 203
Study 24583566 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injectable (RLAI)
Number of subjects: 522
Study 24583795 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-2206 (200 mg weekly)
Number of subjects: 19
Study 24583822 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-azacitidine (AZA)
Number of subjects: 63
Study 24584086 — intervention group
Group type: EXPERIMENTAL
Intervention: Roche High-Pure-System/COBAS(®) TaqMan(®) v2.0 assay (HPS)
Number of subjects: 290
Study 24584086 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbott realtime assay (ART)
Number of subjects: 290
Study 24584086 — intervention group
Group type: COMPARATOR
Intervention: Comparison of HPS and ART
Number of subjects: 290
Study 24584086 — intervention group
Group type: COMPARATOR
Intervention: RGT assessment based on ART
Number of subjects: 290
Study 24584349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fludarabine plus cyclophosphamide
Number of subjects: 555
Study 24584349 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine
Number of subjects: 555
Study 24584349 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 555
Study 24585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to Severe Household Hunger (MSHH)
Number of subjects: 178
Study 24585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF) at 6 months
Number of subjects: 178
Study 24585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding (BF) at 12 months
Number of subjects: 178
Study 24585398 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive Breastfeeding (EBF) between 4 and 6 months
Number of subjects: 178
Study 24585508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid percutaneous coronary intervention (PCI) for ISR CTOs
Number of subjects: 521
Study 24585508 — intervention group
Group type: COMPARATOR
Intervention: Hybrid percutaneous coronary intervention (PCI) for de novo CTOs
Number of subjects: 521
Study 24585508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid PCI for ISR CTOs
Number of subjects: 521
Study 24585508 — intervention group
Group type: COMPARATOR
Intervention: Hybrid PCI for de novo CTOs
Number of subjects: 521
Study 24585716 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical alternans (MA)
Number of subjects: 133
Study 24585716 — intervention group
Group type: EXPERIMENTAL
Intervention: T-wave alternans (TWA)
Number of subjects: 133
Study 24585866 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 24586226 — intervention group
Group type: EXPERIMENTAL
Intervention: TG1042 (adenovirus-interferon-γ)
Number of subjects: 13
Study 24586911 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral transmission clusters (VTCs) identified through phylogenetic analysis and ultra-deep sequencing.
Number of subjects: 690
Study 24586911 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral transmission clusters (VTCs)
Number of subjects: 690
Study 24586911 — intervention group
Group type: COMPARATOR
Intervention: Antiretroviral therapy
Number of subjects: 690
Study 24587068 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention delivered by peer health workers (PHW); included a computer-assisted pre-test, educational video session, and a 6-week group program with weekly meetings.
Number of subjects: 200
Study 24587318 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual depressive symptoms (e.g., sad mood, concentration problems)
Number of subjects: 3703
Study 24588403 — intervention group
Group type: EXPERIMENTAL
Intervention: Group interventions for alcohol/drug dependence and MDD
Number of subjects: 197
Study 24589036 — intervention group
Group type: EXPERIMENTAL
Intervention: Periventricular white matter hyperintensities (PVWMHs)
Number of subjects: 150
Study 24589036 — intervention group
Group type: EXPERIMENTAL
Intervention: Synergistic interactions of WMHs with lacunes
Number of subjects: 150
Study 24589036 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior PVWMHs
Number of subjects: 150
Study 24589294 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg (maximum dose 200 mg) twice a day (bid) plus optimized background regimen (OBR)
Number of subjects: 101
Study 24589294 — intervention group
Group type: EXPERIMENTAL
Intervention: Etravirine 5.2 mg/kg bid plus OBR
Number of subjects: 101
Study 24589669 — intervention group
Group type: EXPERIMENTAL
Intervention: GERD patients
Number of subjects: 48
Study 24590637 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (intravenous, every 2 weeks for up to 96 weeks)
Number of subjects: 107
Study 24590653 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of TH mRNA in PB at diagnosis
Number of subjects: 290
Study 24590653 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of PHOX2B mRNA in PB at diagnosis
Number of subjects: 290
Study 24590653 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of TH, PHOX2B, or DCX mRNA in PB or BM at diagnosis
Number of subjects: 290
Study 24590653 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of TH, PHOX2B, or DCX mRNA in BM after induction therapy
Number of subjects: 290
Study 24590653 — intervention group
Group type: EXPERIMENTAL
Intervention: High TH (log10TH > 0.8) or high PHOX2B (log10PHOX2B > 0.28) in PB
Number of subjects: 290
Study 24590653 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnitude of reduction in mRNA level between diagnosis and postinduction therapy in BM or PB
Number of subjects: 290
Study 24590680 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLf) 100 mg twice a day
Number of subjects: 295
Study 24590680 — intervention group
Group type: COMPARATOR
Intervention: ferrous sulphate 520 mg once a day
Number of subjects: 295
Study 24590680 — intervention group
Group type: EXPERIMENTAL
Intervention: bovine lactoferrin (bLf)
Number of subjects: 295
Study 24590680 — intervention group
Group type: COMPARATOR
Intervention: ferrous sulphate
Number of subjects: 295
Study 24591834 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine
Number of subjects: 2045
Study 24591834 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2045
Study 24593248 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial antibiotic treatment modification (n = 589; 28.9%)
Number of subjects: 2030
Study 24593248 — intervention group
Group type: COMPARATOR
Intervention: No initial antibiotic treatment modification
Number of subjects: 2030
Study 24593656 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to an interactive online care platform for self-management of diabetes.
Number of subjects: 0
Study 24593656 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to laboratory results and educational modules on diabetes through the online platform.
Number of subjects: 0
Study 24593656 — intervention group
Group type: EXPERIMENTAL
Intervention: Economic analyses related to the use of the online platform.
Number of subjects: 0
Study 24593819 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g Osteoset® T with 4% tobramycin sulfate
Number of subjects: 12
Study 24593819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g Osteoset® T with 4% tobramycin sulfate
Number of subjects: 12
Study 24593819 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoset® T (10 g, 30 g, and 50 g)
Number of subjects: 12
Study 24593819 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoset® T
Number of subjects: 12
Study 24594550 — intervention group
Group type: COMPARATOR
Intervention: Overweight patients
Number of subjects: 0
Study 24594550 — intervention group
Group type: COMPARATOR
Intervention: Obese patients
Number of subjects: 0
Study 24594550 — intervention group
Group type: COMPARATOR
Intervention: Morbidly obese patients
Number of subjects: 0
Study 24594550 — intervention group
Group type: COMPARATOR
Intervention: Morbidly obese patients without CT scanning
Number of subjects: 0
Study 24594550 — intervention group
Group type: COMPARATOR
Intervention: Morbidly obese patients with CT scanning
Number of subjects: 0
Study 24594870 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg once daily for 48 weeks
Number of subjects: 90
Study 24595069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oramorph (5 mg every 6 hours)
Number of subjects: 52
Study 24595069 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (M)
Number of subjects: 52
Study 24595069 — intervention group
Group type: EXPERIMENTAL
Intervention: M6G/M ratio
Number of subjects: 52
Study 24595221 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) for 4 weeks
Number of subjects: 70
Study 24595454 — intervention group
Group type: EXPERIMENTAL
Intervention: GIP regimen (gemcitabine 1000 mg/m² on days 1 and 5, ifosfamide 1200 mg/m²/day on days 1-5, cisplatin 20 mg/m²/day on days 1-5, granulocyte colony-stimulating factor 263 μg/day on days 7-15, repeated every 3 weeks for four cycles)
Number of subjects: 37
Study 24595532 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 64
Study 24595628 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analog therapy
Number of subjects: 66726
Study 24595628 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c level
Number of subjects: 66726
Study 24595628 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographical region
Number of subjects: 66726
Study 24595628 — intervention group
Group type: EXPERIMENTAL
Intervention: End-of-study hypoglycemia (insulin-naive group)
Number of subjects: 66726
Study 24595628 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin dose
Number of subjects: 66726
Study 24595628 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life
Number of subjects: 66726
Study 24595633 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training and weight loss (AEX+WL)
Number of subjects: 16
Study 24597398 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic stenosis (AS) valves
Number of subjects: 105
Study 24597398 — intervention group
Group type: COMPARATOR
Intervention: Rheumatic aortic stenosis (RA) valves
Number of subjects: 105
Study 24597398 — intervention group
Group type: COMPARATOR
Intervention: Endocarditis valves
Number of subjects: 105
Study 24597865 — intervention group
Group type: EXPERIMENTAL
Intervention: ZFN-modified autologous CD4 T cells
Number of subjects: 12
Study 24598035 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake and nutritional status assessment through various methods including dietary recall, food frequency questionnaire, and anthropometric measurements.
Number of subjects: 551
Study 24598035 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of malaria parasitemia and intestinal helminth infestation.
Number of subjects: 551
Study 24598452 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 million EBV-CTLs/kg (1-3 doses)
Number of subjects: 11
Study 24598881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk zinc concentration and total milk volume measured using deuterium oxide dose-to-mother tracer technique.
Number of subjects: 46
Study 24598881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk zinc transfer measured using deuterium oxide dose-to-mother tracer technique.
Number of subjects: 46
Study 24598881 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast milk intake measured over time postpartum.
Number of subjects: 46
Study 24598881 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight and length measurements for AGA and SGA infants.
Number of subjects: 46
Study 24599770 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin
Number of subjects: 0
Study 24599770 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0
Study 24600548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (0.5 ng·kg(-1)·min(-1) for 72 hours, then tapered off over 24 hours)
Number of subjects: 46
Study 24600548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 46
Study 24602182 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg IV every 3 weeks
Number of subjects: 30
Study 24603020 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1851
Study 24603117 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg oral treprostinil TID for 7 days
Number of subjects: 19
Study 24603195 — intervention group
Group type: EXPERIMENTAL
Intervention: Prelicence intervention (specific intervention details not provided)
Number of subjects: 7000
Study 24603218 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradient Gel Electrophoresis (GGE)
Number of subjects: 136
Study 24603218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical Auto Profile Ultracentrifugation (VAP-II)
Number of subjects: 136